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Abstract
Background: Chronic antigenic stimulation by cytomegalovirus (CMV) is thought to increase ‘‘immunosenesence’’ of aging,
characterized by accumulation of terminally differentiated CD28- CD8+ T cells and increased CD57, a marker of proliferative
history. Whether chronic HIV infection causes similar effects is currently unclear.
Methods: We compared markers of CD8+ T cell differentiation (e.g., CD28, CD27, CCR7, CD45RA) and CD57 expression on
CD28- CD8+ T cells in healthy HIV-uninfected adults with and without CMV infection and in both untreated and
antiretroviral therapy (ART)-suppressed HIV-infected adults with asymptomatic CMV infection.
Results: Compared to HIV-uninfected adults without CMV (n = 12), those with asymptomatic CMV infection (n = 31) had a
higher proportion of CD28-CD8+ T cells expressing CD57 (P = 0.005). Older age was also associated with greater proportions
of CD28-CD8+ T cells expressing CD57 (rho: 0.47, P = 0.007). In contrast, untreated HIV-infected CMV+ participants (n = 55)
had much lower proportions of CD28- CD8+ cells expressing CD57 than HIV-uninfected CMV+ participants (P,0.0001) and
were enriched for less well-differentiated CD28- transitional memory (TTR) CD8+ T cells (P,0.0001). Chronically HIV-infected
adults maintaining ART-mediated viral suppression (n = 96) had higher proportions of CD28-CD8+ T cells expressing CD57
than untreated patients (P,0.0001), but continued to have significantly lower levels than HIV-uninfected controls
(P = 0.001). Among 45 HIV-infected individuals initiating their first ART regimen, the proportion of CD28-CD8+ T cells
expressing CD57 declined (P,0.0001), which correlated with a decline in percent of transitional memory CD8+ T cells, and
appeared to be largely explained by a decline in CD28-CD57- CD8+ T cell counts rather than an expansion of CD28-CD57+
CD8+ T cell counts.
Conclusions: Unlike CMV and aging, which are associated with terminal differentiation and proliferation of effector memory
CD8+ T cells, HIV inhibits this process, expanding less well-differentiated CD28- CD8+ T cells and decreasing the proportion
of CD28- CD8+ T cells that express CD57.
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Introduction
Despite effective antiretroviral therapy (ART), HIV-infected
individuals remain at higher risk for aging-related diseases (e.g.,
heart disease, cancer, and bone disease) and death than the
general population [1]. HIV also causes several defects in the
immune system that appear similar to those observed in elderly
populations, which has raised the hypothesis that HIV causes
accelerated aging of the immune system, or ‘‘immunosenescence
[1].’’ T cell senescence, whether driven by aging and/or by
chronic antigenic stimulation from pathogens such as cytomega-
lovirus (CMV), is typically characterized by the accumulation of
terminally differentiated CD8+ T cells with shortened telomeres,
the loss of expression of the co-stimulatory molecule CD28, and
increased expression of CD57, a marker of proliferative history
and poor proliferative capacity [2].
While the loss of CD28 expression on CD8+ T cells is
characteristic of HIV infection, the impact of HIV on CD57
expression on CD8+ T cell subsets – particularly the effector
memory CD8+ T cell subsets that normally express CD57 - is less
well established. HIV-specific CD8+ T cells are more likely to
express CD57 than non-HIV-specific CD8+ T cells [3], and CD57
expression is increased on the total memory CD8+ T cell
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population in HIV infection [4,5], but much of this increase could
be explained by relative enrichment for effector CD28- CD8+ T
cells over central memory and naı̈ve CD8+ T cells (which rarely
express CD57). Indeed, a recent report suggests that an
abnormally low proportion of terminally differentiated CD45RA+
CD28-CCR7- CD8+ T cells express CD57 in untreated HIV
infection, consistent with the possibility that these cells had
completed fewer prior rounds of proliferation in vivo [6]. CD57
expression was also a much less consistent correlate of clinical
progression in untreated HIV infection than the loss of CD28
expression on CD8+ T cells [4].
In the current study, we sought to better characterize the effect
of HIV on the proportion of CD28-CD8+ T cells expressing
CD57 and to compare these effects with those observed in aging
and chronic asymptomatic CMV infection. Our data suggest that
asymptomatic CMV infection and advancing age are both
associated with increased terminal differentiation and a high
proportion of CD28-CD8+ T cells expressing CD57, consistent
with the ‘‘immunosenescent’’ phenotype of aging. In contrast,
untreated HIV infection leads to enrichment for less well-
differentiated transitional cells and lower proportions of CD28-
CD8+ T cells expressing CD57. Though these abnormalities
improve during suppressive ART, they fail to normalize in
chronically HIV-infected individuals. Collectively, these data
suggest that the phenotypic CD8+ T cell abnormalities of
untreated and treated HIV infection are distinct from those of
chronic CMV infection and aging.
Materials and Methods
Ethics statement
All participants provided written informed consent, this
research was approved by the institutional review boards of the
University of California, San Francisco and the Mbarara
University of Science and Technology, and all studies were
conducted according to the principles expressed in the Declaration
of Helsinki.
Participants
For the cross-sectional comparisons, HIV-uninfected partici-
pants with and without asymptomatic CMV infection as well as
chronically untreated HIV-infected patients (.1 year following
sero-conversion) were sampled from the SCOPE and OPTIONS
cohorts in San Francisco as previously described [7,8]. HIV-
infected individuals maintaining ART-mediated viral suppression
(,75 copies HIV RNA/ml plasma) were sampled from the
SCOPE cohort. For longitudinal assessment of changes in T cell
subsets during early ART-mediated viral suppression, participants
were also sampled from the Uganda Antiretroviral Treatment
Outcomes (UARTO) cohort, a rural, clinic-based cohort of 750
chronically HIV-infected patients initiating their first ART
regimen at the Mbarara University of Science and Technology
HIV Clinic, Uganda.
Laboratory methods
T cell phenotyping was performed on cryopreserved peripheral
blood mononuclear cells (PBMCs), as described previously [9].
Cells were thawed, washed, stained with LIVE/DEADH Fixable
Aqua Dead Cell Stain Kit (Invitrogen), excluding non-viable cells
and stained with fluorescently-conjugated monoclonal antibodies
including: CD3-Pacific Blue and CD28-PE-CyTM5 (BD Pharmin-
gen); CD8-QDOTH605 and CD4-PE-Texas RedH (Invitrogen);
CD45RA-PE, CD31-FITC, CCR7-PE-CYTM7 (all BD Bios-
cences); CD57-Alexa Fluor H647 (Biolegend); and CD27-APCe-
FluorH780 (eBioscience). Cells were fixed in 0.5% formaldehyde
and data were acquired on a LSR II Flow cytometer (BD
Biosciences), with $250,000 lymphocytes collected. CPT beads
(BD Bioscience) were used for instrument set up for each run and
Rainbow beads (Spherotec) for standardized instrument settings
between runs. Aliquots of a control specimen were thawed with
every run and used to confirm run-to-run reproducibility. FMO
controls were also prepared on controls for each run to check that
gates were set consistently between runs. Data was compensated
and analyzed in FlowJo V9 (TreeStar). Gates were set to define
positive expression of each maturation marker and Boolean gates
were calculated to determine the %CD8+ T cells that expressed
combinations of CD45RA, CCR7, CD27, CD28 and CD57. For
some populations, results obtained from Boolean combinations
were confirmed by gating directly visualized populations to
confirm the validity of the Boolean gating approach. Maturational
T cell subsets were defined as naı̈ve TN (CD28+CD27+CCR7+
CD45RA+), central memory TCM (CD28+CD27+CCR7+
CD45RA-), as well as the following CD28- populations: transi-
tional TTR (CD28-CD27+CCR7-CD45RA-), effector memory,
TEM (CD28-CD27-CCR7-CD45RA-), and terminally differenti-
ated, TEMRA (CD28-CD27-CCR7-CD45RA+). Chronic asymp-
tomatic CMV infection was confirmed as a positive CMV IgG
titer and for a subset of HIV-infected participants without
available CMV serology, .0.1% pp65/IE-specific IFN-c+
CD8+ T cell responses by cytokine flow cytometry (10-fold
increase over limit of detection) as previously described [10].
Table 1. Characteristics of SCOPE and OPTIONS participants by CMV and HIV status.
SCOPE and OPTIONS
HIV-CMV-Median
(IQR) (n = 12)
HIV-CMV+ Median (IQR)
(n = 31)
*HIV+ART+ Median
(IQR) (n = 96)
*HIV+ART-Median
(IQR) (n = 55)
Age, years** 35 (34–50) 41 (34–45) 51 (45–57) 40 (34–44)
Male gender, No. (%) 11 (92%) 29 (94%) 84 (88%) 52 (95%)
Proximal CD4+ count, cells/mm3** NA NA 592 (448–738) 407 (314–504)
Proximal HIV RNA level, log10copies/mL
** NA NA #1.6 4.4 (4.1–4.6)
Pre-ART nadir CD4+ count, cells/mm3 NA NA 110 (49–180) NA
Duration of viral suppression, years NA NA 4 (2–9) NA
* All CMV+.
** Difference among groups (Kruskal-Wallis or Wilcoxon ranksum test), P,0.001.
doi:10.1371/journal.pone.0089444.t001
CD8+ T Cell CD57 Expression in CMV and HIV
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Statistical methods
Cross-sectional pairwise comparisons between groups were
performed using Wilcoxon rank sum tests. Changes in T cell
subsets during the first six months of ART-mediated viral
suppression in the UARTO cohort were analyzed using Wilcoxon
signed rank tests. Adjusted comparisons were assessed with linear
regression. Since age is an important determinant of CD57
expression, we considered age a confounder in all adjusted
analyses. Since some comparator groups had insufficient female
participants to assess gender effects, we restricted adjusted analyses
to male participants. Since CMV is an important determinant of
CD57 expression, and since almost all HIV-infected participants
were CMV co-infected, we restricted all comparisons between
HIV+ and HIV- participants to those with confirmed asymptom-
atic CMV infection. Relationships between continuous variables
were assessed with Spearman’s rank order correlation coefficients.
Variables in logistic and/or linear regression models were
transformed as necessary to satisfy model assumptions. Statistical
analyses were performed using STATA Version 12 (StataCorp LP,
Texas), 2011.
Results
Impact of CMV and age on CD57 expression in HIV-
uninfected Individuals
We first assessed the impact of CMV and age on CD8+ T cell
CD28 and CD57 expression in 43 healthy, asymptomatic HIV-
uninfected participants with a median age of 44 (Table 1). Since
nearly all CD57+ CD8+ T cells are CD28- (Figure S1), we
assessed not only the proportion of CD28-CD57+ CD8+ T cells (a
commonly reported senescence phenotype in the aging literature),
but also the proportion of CD28-CD8+ T cells that express CD57.
Compared to CMV-seronegative participants (n = 12), CMV-
seropositive participants (n = 31) had a higher median percent
CD28- CD8+ T cells (38% vs. 13%, P = 0.0004), percent CD28-
CD57+ CD8+ T cells (22% vs. 5%, P = 0.001), and proportion of
CD28-CD8+ T cells expressing CD57 (64% vs. 49%, P = 0.005,
Figure 1. Effects of CMV and age on the proportion of CD28-CD8+ T cells expressing CD57. The proportion of CD28- and CD28-CD57+
CD8+ T cells (A), of CD28-CD8+ T cells expressing CD57 (B), and of maturational subsets of CD28- CD8+ T cells: transitional memory, TTR, (CD28-
CD27+CCR7-CD45RA-) and terminally differentiated, TTEMRA, (CD28-CD27-CCR7-CD45RA+) CD8+ T cells (C), were compared between HIV-uninfected
asymptomatic CMV-seronegative (green) and CMV-seropositive (blue) participants. Bars represent median values. The correlation between the
proportion of CD28-CD8+ T cells expressing CD57 and age was also assessed among CMV-seropositive HIV-uninfected adults (D). The red line
represents a linear prediction.
doi:10.1371/journal.pone.0089444.g001
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Figure 1A–B). Much of this enrichment appeared to be explained
by an expansion of CD28-CD57+ CD8+ T cell counts in CMV-
seropositive compared to CMV-seronegative participants (median
63 vs. 24 cells/mm3, P = 0.01, data not shown). All of these
differences remained significant after adjustment for age and
restricting to men (P#0.009 for all). Asymptomatic CMV infection
was also associated with enrichment for terminally differentiated,
TEMRA, (CD28-CD27-CCR7-CD45RA+) CD8+ T cells
(P = 0.0004, Figure 1C), which also remained significant after
adjustment for age and restricting to men (P = 0.001).
Increasing age was also associated with these T cell abnormal-
ities, even in this relatively young sample of HIV-uninfected
individuals. Older age was strongly associated with a higher
proportion of CD28-CD8+ T cells expressing CD57 in the subset
of CMV-seropositive HIV-uninfected participants (rho: 0.47,
P = 0.007, Figure 1D), but there was no evidence for an association
between age and the %CD28- CD8+ T cells (rho: 0.01, P = 0.97)
or the %TEMRA CD8+ T cells (rho: 0.08, P = 0.67). Among all
HIV-uninfected participants, each ten-year increase in age was
associated with a mean 2% increase in the proportion of CD28-
CD8+ T cells expressing CD57(P = 0.04), after adjusting for CMV
status. We lacked sufficient numbers of CMV seronegative
individuals to assess whether CMV serostatus modifies the
association between age and the proportion of CD28-CD8+ T
cells expressing CD57.These data confirm that CMV and age
increase the proportion of CD28- CD8+ T cells that express CD57
and extend previous findings in elderly cohorts [11] to a cohort of
much younger adults.
Impact of chronic HIV infection and ART on CD57
expression
To assess differences between HIV-uninfected and HIV-
infected individuals, we restricted all analyses to CMV-infected
participants since nearly all HIV-infected individuals in our
cohorts are CMV co-infected. HIV-infected participants were
mostly men and slightly older than the HIV-uninfected partici-
pants (Table 1). While the 55 untreated HIV-infected participants
had a higher median percent CD28- CD8+ T cells than HIV-
uninfected controls (69% vs. 38%, P,0.0001), they had a much
lower median proportion of CD28-CD8+ T cells expressing
CD57(39% vs. 64%, P,0.0001, Figure 2A–B). These competing
effects resulted in similar percentages of CD28-CD57+ CD8+ T
cells between HIV-infected and uninfected participants. While the
96 ART-suppressed participants had a higher median proportion
of CD28-CD8+ T cells expressing CD57 than untreated
participants (52% vs. 39%, P,0.0001), they had lower levels than
HIV-uninfected controls (P = 0.001), despite a median of 4 years of
ART-mediated viral suppression (Figure 2B). Untreated and
ART-suppressed HIV-infected participants also had abnormally
low proportions of CD57+ cells within each CD28- CD8+ T cell
maturational subset compared to HIV negative controls (P#0.03,
Figure S2). The abnormally low proportion of CD28-CD8+ T
Figure 2. Effects of HIV and ART on CD8+ T cell subset counts. Total CD8+ T cell and CD28- CD8+ T cell (A), CD28-CD57+ and CD28-CD57-
CD8+ T cell (B), and transitional memory, TTR, (CD28-CD27+CCR7-CD45RA-) and terminally differentiated, TTEMRA, (CD28-CD27-CCR7-CD45RA+) CD8+
T cell (C) counts were compared between HIV-uninfected (blue), ART-suppressed (red), and untreated viremic (purple) HIV-infected individuals. All
comparisons were restricted to CMV-infected participants. Bars represent median values.
doi:10.1371/journal.pone.0089444.g002
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cells expressing CD57 in untreated and ART-suppressed partic-
ipants appeared to be primarily explained by an expansion of
CD28-CD57- CD8+ T cells rather than a decline in CD28-
CD57+ CD8+ T cell counts (Figure 3B). Thus, while CMV and
aging appear to expand CD28-CD57+ CD8+ T cell populations,
HIV appears to preferentially expand CD28-CD57- CD8+
populations, an effect which fails to completely normalize with
suppressive ART.
Consistent with previously published work [12], untreated HIV-
infected participants also had a higher median percent and count
of transitional memory, TTR, (CD28-CCR7-CD27+CD45RA-)
CD8+ T cells than HIV-uninfected participants (7.3% vs.1.8%,
P,0.0001; 74 vs. 8 cells/mm3, P,0.0001, Figure 2C and 3C).
While ART-suppressed participants had somewhat lower percent
TTR CD8+ T cells than untreated participants, they continued to
have higher median levels than HIV-uninfected controls (2.9% vs.
1.8%, P = 0.0005). Among ART-suppressed participants, lower
proportions of CD28-CD8+ T cells expressing CD57 were also
associated with higher %TTR CD8+ T cells (R = 20.25, P = 0.01,
Figure 2D).
Longitudinal ART-mediated changes in CD8+ T cell
differentiation and CD57 expression
To characterize longitudinal changes in CD8+ T cell differen-
tiation and CD57 expression during early ART, we assessed 45
ART-naı̈ve HIV-infected adult Ugandans before and after 6
months of suppressive ART in the UARTO cohort. Participants
were mostly female and young, and had relatively low pre-ART
CD4+ counts and high pre-ART HIV RNA levels (Table 2).
While the median percent CD28- CD8+ T cells decreased during
early ART (77% to 60%, P,0.0001), the percent CD28-CD57+
CD8+ T cells increased (16% to 21%, P,0.0001), as did the
proportion of CD28-CD8+ T cells expressing CD57 (24% to 38%,
P,0.0001, Figures 4A–C). The percent of CD8+ TTR cells also
declined during early ART (Figure 4D) and those experiencing the
greatest declines in percent CD8+ TTR also tended to experience
the greatest increase in the proportion of CD28-CD8+ T cells
expressing CD57 (rho: 20.44, P = 0.003, Figure 4E).
The increase in the proportion of CD28-CD8+ T cells
expressing CD57 during early ART appeared to be driven by a
decline in CD28-CD57- CD8+ T cell counts (median 463 to
246 cells/mm3, P,0.0001, Figure 5C), without evidence for a
change in CD28-CD57+ CD8+ T cell counts (median 137 to 137
cells, P = 0.26, Figure 5D). While median central memory CD8+
T cell counts actually increased during 6 months of ART (48 to
60 cells/mm3, P = 0.0006, Figure 5A), all maturational subsets of
CD28- CD8+ T cells declined: TTR (52 to 24 cells/mm3, P,
0.0001), TEM, effector memory (CD28-CD27-CCR7-CD45RA-,
129 to 69 cells/mm3, P,0.0001), and TEMRA (126 to 103 cells/
mm3, P = 0.05) cells, with the smallest declines in the most
terminally differentiated TEMRA cells (Figure S3).
Figure 3. Effects of HIV and ART on the proportion of CD28-CD8+ T cells expressing CD57. The proportions of CD28- CD8+ T cells, CD28-
CD57+ CD8+ T cells (A), of CD28-CD8+ T cells expressing CD57 (B), and of maturational subsets of CD28- CD8+ T cells: transitional memory, TTR,
(CD28-CD27+CCR7-CD45RA-) and terminally differentiated, TTEMRA, (CD28-CD27-CCR7-CD45RA+) CD8+ T cells (C), were compared between HIV-
uninfected (blue), ART-suppressed (red), and untreated viremic (purple) HIV-infected individuals. All comparisons were restricted to CMV-infected
participants. Bars represent median values. The correlation between the proportion of CD28-CD8+ T cells expressing CD57 and the percent TTR CD8+
T cells was also assessed in HIV-infected ART-suppressed participants (D).
doi:10.1371/journal.pone.0089444.g003
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Discussion
While CD57 expression on CD8+ T cells has long been
associated with CMV infection, immunosenescence, and mortality
risk in elderly HIV-uninfected populations [11,13,14], the impact
of HIV on this marker has been less well characterized. In the
current study, we confirm that CMV infection and advancing age
increase CD57 expression on CD28- CD8+ T cells even in a much
younger HIV-uninfected population than has been previously
described [11]. We also demonstrated that unlike CMV and aging,
HIV causes an expansion of less well-differentiated transitional
memory CD8+ T cells and CD28-CD57- CD8+ T cells (resulting
in an abnormally low proportion of CD28-CD8+ T cells
expressing CD57), which partially reverses, but fail to normalize
during suppressive ART. Thus, the phenotypic abnormalities in
CD8+ T cells associated with both untreated and treated HIV
infection are actually quite distinct from those associated with
CMV infection and aging.
Aging and CMV both increase the proportion of CD28-CD8+
T cells expressing CD57 [2,15], and higher percent CD28-CD57+
CD8+ T cells predict mortality in the HIV-uninfected elderly
population [11]. Many have hypothesized that the chronic
inflammatory state of HIV infection would cause similar CD8+
Table 2. Characteristics of HIV-infected Ugandans starting
ART.
Characteristic
Median (IQR)
(n = 45)
Age, years 36 (31–40)
Male gender, No., (%) 15 (33%)
Pre-ART nadir CD4+ count, cells/mm3 176 (124–236)
Pre-ART plasma HIV RNA level, log10copies/mL 5.1 (4.7–5.8)
Month 6 CD4+ count, cells/mm3 269 (211–388)
doi:10.1371/journal.pone.0089444.t002
Figure 4. Impact of initial ART-mediated viral suppression on CD8+ T cell CD57 expression and percent transitional cells. Changes in
the percent of CD28- CD8+ T cells (A), CD28-CD57+ CD8+ T cells (B), CD28-CD8+ T cells expressing CD57 (C), and CD28- transitional memory, TTR,
(CD27+CCR7-CD45RA-) CD8+ T cells (D) are plotted over the first 6 months of ART-mediated viral suppression is plotted for 45 chronically HIV-
infected Ugandans initiating their first ART regimen. Individual trajectories are shown in red and median trajectories with heavy black lines. The
correlation between the ART-mediated change in the proportion of CD28-CD8+ T cells expressing CD57 and the ART-mediated change in %TTR CD8+
T cells was also assessed (E).
doi:10.1371/journal.pone.0089444.g004
CD8+ T Cell CD57 Expression in CMV and HIV
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T cell phenotypic defects [16,17]. Although HIV infection leads to
an expansion of CD28- CD8+ T cells similar to that observed with
CMV and aging, HIV results in an abnormally low proportion of
these cells that express CD57. This phenomenon may be the
reason why prior studies failed to observe decreases in percent
CD28-CD57+ CD8+ T cells during ART [18,19], since the
percent CD28- CD8+ T cells declines while the proportion of
these cells expressing CD57 increases during treatment. Indeed,
the clinical relevance of the percent CD28-CD57+ CD8+ T cells is
unclear in HIV infection. While a single study suggested that
higher percent CD28-CD57+ CD8+ T cells were associated with
greater atherosclerosis in HIV-infected women, it was unclear
whether this association was independent of CD8+ T cell
activation (or innate immune activation) [9]. The only two studies
to date that have assessed the association between the percent
CD28-CD57+ CD8+ T cells and mortality in treated HIV
infection have tended to show decreased mortality in ART-
suppressed individuals with higher frequencies of these cells
[20,21]. This raises the possibility that a decreased proportion of
CD28-CD8+ T cells expressing CD57 in HIV-infected individuals
might actually predict increased morbidity and mortality, a
question we are addressing in a separate study [22].
The physiologic significance of abnormally low proportions of
CD28-CD8+ T cells expressing CD57 in HIV infection remains
unclear. Much of the discussion on CD57+ CD8+ T cells in the
aging literature has focused on the impaired ability of these cells
to proliferate upon in vitro stimulation and their propensity to
secrete inflammatory cytokines, properties that have been
used to explain the observed association between high
CD57 expression and mortality in the elderly population
[23,24,25,26,27,28,29,30,31,32,33,34,35]. Nevertheless, high
CD57 expression may also reflect a greater proliferative history
of memory CD8+ T cells in vivo. Indeed, CD57+ CD8+ T cells at
any given maturational stage have shorter telomere length and
lower T cell receptor excision circle (TREC) content than CD57-
CD8+ T cells from HIV-infected individuals [3]. Thus, abnor-
mally low proportions of effector CD8+ T cells expressing CD57
in both untreated and treated HIV infection may reflect an
impaired ability to successfully complete terminal differentiation
and multiple rounds of cell division in response to antigens in vivo,
Figure 5. Impact of initial ART-mediated viral suppression on CD8+ T cell subset counts. Changes in central memory, TCM, (CD28+CD27+
CCR7+CD45RA-) (A), CD28- (B), CD28-CD57- (C), and CD28-CD57+ CD8+ T cell counts (D) are plotted over the first six months of ART-mediated viral
suppression for 45 chronically HIV-infected Ugandans initiating their first ART regimen. Individual trajectories are shown in red and median
trajectories with heavy black lines.
doi:10.1371/journal.pone.0089444.g005
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which might result in a functional immune defect that is distinct
from what is observed in CMV and aging. This concept is
illustrated in our proposed model, whereby naı̈ve and central
memory CD8+ T cells normally give rise to multiple rounds of
effector CD8+ T cell proliferation and terminal differentiation
upon exposure to their cognate antigens (Figure 6A). The resultant
CD57+ TEMRA cells may be resistant to further proliferation in
vitro, but are likely highly effective at killing infected cells [36]. This
hypothesis is consistent with an early observation that higher
percent CD57+ CD8+ T cells are associated with lower plasma
HIV RNA level set-points in individuals with recent HIV infection
[37]. Chronic antigenic stimulation due to CMV infection appears
to accelerate cell proliferation and differentiation leading to
enrichment for TEMRA CD8+ T cells which have undergone
several rounds of cell division and subsequently express CD57
(Figure 6B). We propose that in HIV infection, while inflamma-
tory cytokines and antigens drive more naı̈ve and central memory
CD8+ T cells into cell cycle, the resultant effector CD28- CD8+ T
cells undergo fewer rounds of proliferation and fail to terminally
differentiate [22], leading to enrichment for less well-differentiated
transitional memory cells, with perhaps poorer killing capacity
(Figure 6C). Given recent data that CD57+ cells express
chemokine receptors such as CX3CR1 that promote migration
to non-lymphoid tissues [38], there is the possibility our
observations may simply be due to the redistribution of CD28-
CD8+ T cells that express CD57 into highly infected tissues.
Figure 6. Schematic of CD8+ T cell differentiation and CD57 expression in HIV-uninfected and HIV-infected individuals. In HIV-
uninfected and CMV-uninfected individuals, when a central memory CD8+ T cell sees its cognate antigen, it undergoes a burst of cellular proliferation
and differentiation, and many - but not all - effector CD28-CD8+ T cells complete terminal differentiation and/or undergo several rounds of cell
division (A). The cells that have undergone multiple rounds of proliferation and become terminally differentiated tend to express CD57.
Asymptomatic CMV infection causes even greater proliferation and terminal differentiation of CD28-CD8+ T cells, resulting in multiple completed
rounds of cell division and enrichment for TEMRA cells that express CD57 (B). When CMV-seropositive individuals are infected with HIV, they
experience an even greater expansion of CD28-CD8+ T cells, but a smaller proportion of these cells undergo successful proliferation and terminal
differentiation, resulting in enrichment for less well-differentiated TTR cells and lower CD57 expression on CD28- cells (C). CD57- memory CD8+ T cells
are shown in orange, and cells expressing CD57 shown in green.
doi:10.1371/journal.pone.0089444.g006
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Therefore, our hypothesized model will need to be formally tested
in subsequent in vitro and in vivo studies directly measuring T cell
proliferation, cytotoxicity, and/or vaccine responsiveness and/or
examining changes in tissues to determine whether the HIV-
associated decrease in the proportion of CD28-CD8+ T cells
expressing CD57 truly reflects a functional effector T cell defect.
Non-isotopic labeling studies may also be help clarify the degree to
which the expansion of CD28-CD57- CD8+ T cells observed in
HIV infection is driven by increased proliferation versus a failure
of these cells to die or terminally differentiate. Finally, the cross-
sectional and longitudinal cohorts are from very different
populations with potentially different co-pathogens that could
have affected the percentage of CD28-CD8+ T cells expressing of
CD57. However, the inferences were very similar between these
cohorts, suggesting that the effect of HIV on this phenotype is
likely to be independent of these demographic and environmental
differences. We also observed similar results in another U.S.-based
longitudinal cohort of individuals [22]. Lastly, it is important to
emphasize that both cohorts in the current study had very
advanced HIV infection at the time of ART initiation, so it
remains unclear whether these results would be generalizable to
HIV-infected individuals initiating ART at earlier stages of
infection.
In summary, we found that the persistent phenotypic CD8+ T
cell defects of treated HIV infection are distinct from those
observed with CMV infection or aging-associated immunosenes-
cence. While HIV leads to an expansion of CD28- CD8+ T cells,
fewer of these cells may be able to successfully complete T cell
maturation and proliferation, leading to an overall decrease in the
proportion of these cells that express CD57. By examining the
proportion of CD28- CD8+ T cells that express CD57 (rather than
the proportion of the entire CD8+ T cell population expressing
CD57 as has been assessed in prior studies [3,4,9]), our study
provides insights into a unique CD8+ T abnormality that appears
to be different from aging-associated immunosenescence. Future
studies will need to clarify the prognostic importance of these
abnormalities on clinical outcomes as well as the impact of these
abnormalities on CD8+ T cell function in HIV-infected individ-
uals.
Supporting Information
Figure S1 CD57 expression on CD28+ and CD28- CD8 +
T cells in HIV-uninfected individuals. A flow cytometry plot
from a representative HIV-uninfected CMV-seropositive individ-
ual assessing CD28 and CD57 expression on CD8+ T cells (gated
on total CD3+CD8+ T cells, CD57 gate set with FMO control) is
shown (A). The percent of each population relative to the total
CD8+ T cell population is depicted in blue font and the
proportion of CD28+ and CD28- cells expressing CD57 is
depicted in green font. The proportion of CD28+ (orange) and
CD28- (purple) CD8+ T cells expressing CD57 was also compared
among all HIV-uninfected individuals (B), demonstrating that
CD57 expression is primarily observed among CD28- CD8+ T
cells.
(TIFF)
Figure S2 Effects of HIV and ART on the proportion of
CD28-CD8+ T cells expressing CD57 by maturational
subset. The proportion of transitional memory, TTR, (CD27+
CCR7-CD45RA-) (A), effector memory, TEM, (CD27-CCR7-
CD45RA-) (B), and terminally differentiated, TTEMRA, (CD27-
CCR7-CD45RA+) (C) CD28- CD8+ T cells that express CD57
were compared between HIV-uninfected individuals (blue), HIV+
ART-suppressed (red), and HIV+ untreated viremic (purple)
individuals. Bars represent median values. All comparisons were
restricted to CMV-positive individuals.
(TIFF)
Figure S3 Impact of ART-mediated viral suppression on
cell counts of CD8+ T cell maturational subsets. Changes
in the cell counts of central memory, TCM, (CD28+CD27+
CCR7+CD45RA-) (A), CD28- transitional memory, TTR, (CD28-
CD27+CCR7-CD45RA-) (B), effector memory, TEM (CD28-
CD27-CCR7-CD45RA-) (C), and terminally differentiated,
TEMRA (CD28-CD27-CCR7-CD45RA+) CD8+ T cells (D) are
plotted over the first six months of ART-mediated viral
suppression for 45 HIV-infected Ugandans initiating their first
ART regimen. Individual trajectories are shown in red and
median trajectories with heavy black lines.
(TIFF)
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